New US agreement proclaimed "significant milestone” for Swedish biotech company
Swedish Inficure Bio has signed an agreement with a publicly listed US biopharmaceutical company that develops drugs for several chronic and life-threatening diseases.
“We will now begin testing the effects of their drug substances in our unique model. The company is world-leading in drug development, so this recognition is significant for us,” says Inficure Bio’s CEO, Sofia Mayans.
Inficure Bio has developed a more accurate and faster way for pharmaceutical companies that want to test the efficiency of new drugs that treat fibrosis. Fibrosis, or scar tissue, is the body's natural way of repairing damaged and inflamed tissue. If, however, this process continues unchecked, large amounts of fibrosis can accumulate in the tissue and the organ’s function becomes compromised. Fibrosis can occur as a consequence of, for example, fatty liver or other low-intensity inflammatory conditions that are linked to obesity and type 2 diabetes.
The Umeå-based company has recently signed an agreement with the publicly listed company to test their drug candidates in Inficure Bio's unique preclinical model, named the NIF model.
“The fact that they want to use our NIF model is recognition of its value. The company has extensive expertise in fibrosis and clinical development of innovative drugs for the treatment of fibrotic disease and cancer. So this agreement is very important to us - both financially and in terms of marketing,” says Sofia Mayans, and continues:
“In addition we’re continuing our work to find more customers in the US, Europe and Australia. We also plan to introduce our NIF model to the Korean market”.
Inficure Bio has previously signed several major agreements, including one with another stock market-listed US pharmaceutical manufacturer and a Swiss pharmaceutical company.
For further information please contact:
Sofia Mayans, PhD, CEO Inficure Bio
+46 70-366 46 66
About Inficure Bio
Inficure Bio is a life science company focused on preclinical development of drugs for treatment of chronic inflammatory and fibrotic conditions. The company has a panel of preclinical models, including a unique model, for studies of chronic inflammation and fibrosis.
Inficure Bio is based on extensive expertise in immunology, inflammation and fibrosis and offers a competent and flexible service in this area.
By conducting preclinical tests, Inficure Bio contributes to the development of new drugs for chronic inflammation and fibrosis, which increases the quality of life of the individuals affected by these diseases. Inficure Bio operates in a global market with customers in e.g. Australia, US and Europe.
Umeå Biotech Incubator (UBI) is one of Sweden’s state-of-the-art business incubators within the life sciences. We help researchers to use their data to the benefit of patients and citizens, improving their health. We support and train entrepreneurs in the fields of pharmaceuticals, diagnostics and medical engineering, and act as a bridge between academia, medicine and the business community.